Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

NCT03712605 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03712605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03712605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 15, 2018
Completion date
December 31, 2026
Enrollment
280 (estimated)
Sites
552

Conditions

As the registry lists them; a condition with its own page is linked.

pathologic stage i cutaneous merkel cell carcinoma ajcc v8, pathologic stage ii cutaneous merkel cell carcinoma ajcc v8, pathologic stage iii cutaneous merkel cell carcinoma ajcc v8